相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Characterization and Optimization of Multiplexed Quantitative Analyses Using High-Field Asymmetric-Waveform Ion Mobility Mass Spectrometry
Devin K. Schweppe et al.
ANALYTICAL CHEMISTRY (2019)
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1
Masashi Namba et al.
CANCER LETTERS (2019)
Accurate Quantitative Proteomic Analyses Using Metabolic Labeling and High Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)
Sibylle Pfammatter et al.
JOURNAL OF PROTEOME RESEARCH (2019)
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Suhas Vasaikar et al.
CELL (2019)
TMT Labeling for the Masses: A Robust and Cost-efficient, In-solution Labeling Approach
Jana Zecha et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast
Clare D'Arcy et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
A Curated Resource for Phosphosite- specific Signature Analysis
Karsten Krug et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
H. Rudolf de Boer et al.
ONCOGENE (2019)
Comprehensive Single-Shot Proteomics with FAIMS on a Hybrid Orbitrap Mass Spectrometer
Alexander S. Hebert et al.
ANALYTICAL CHEMISTRY (2018)
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
Filip Mundt et al.
CANCER RESEARCH (2018)
Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry
Philipp Mertins et al.
NATURE PROTOCOLS (2018)
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups
Tenley C. Archer et al.
CANCER CELL (2018)
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Leila Farahmand et al.
CURRENT CANCER DRUG TARGETS (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer
Ryoichi Matsunuma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Maria F. Mercogliano et al.
CLINICAL CANCER RESEARCH (2017)
Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction
Jing Wang et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer
Xiaozheng Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2017)
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Michael A. Gordon et al.
MOLECULAR CANCER THERAPEUTICS (2017)
MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701
Chia-Hung Chen et al.
MOLECULAR ONCOLOGY (2017)
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
Kuan-lin Huang et al.
NATURE COMMUNICATIONS (2017)
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
Charles Caldwell et al.
SCIENTIFIC REPORTS (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu et al.
CANCER AND METASTASIS REVIEWS (2016)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang et al.
CELL (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient
Eva Dazert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Anthony Ferrari et al.
NATURE COMMUNICATIONS (2016)
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab A Secondary Analysis of the HERA Trial
Sherene Loi et al.
JAMA ONCOLOGY (2016)
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Tiannan Guo et al.
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
CopywriteR: DNA copy number detection from off-target sequence data
Thomas Kuilman et al.
GENOME BIOLOGY (2015)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang et al.
NATURE (2014)
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D. Raina et al.
ONCOGENE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
EUROPEAN JOURNAL OF CANCER (2005)
Tandem mass tags:: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS
A Thompson et al.
ANALYTICAL CHEMISTRY (2003)
Muc4/sialomucin complex in the mammary gland and breast cancer
KL Carraway et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2001)
Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer
D Dankort et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)